Comparison of D2 and D3 dopamine receptor affinity of dopaminergic compounds in rat brain

Life Sciences

Volumn 62, Issue 20, 1998, Pages 1825-1831

  Flietstra, Rebecca J ^a   Levant, Beth ^a,b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

D2 dopamine receptor; D3 dopamine receptor; Striatum; Vestibulocerebellum; 3H quinpirole

Indexed keywords

2 DIPROPYLAMINO 5 METHOXY 1 METHYLTETRALIN; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; 7 HYDROXY 2 [N PROPYL N (3' IODO 2' PROPENYL)AMINO]TETRALIN; CHLORPROMAZINE; DOMPERIDONE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; METHACRYLIC ACID METHYL ESTER; NAFADOTRIDE; PD 152255; QUINELORANE; QUINPIROLE; RISPERIDONE; TRITIUM; UNCLASSIFIED DRUG; DOPAMINE RECEPTOR BLOCKING AGENT; DRD3 PROTEIN, RAT;

ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; CAUDATE NUCLEUS; CEREBELLUM; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; MALE; NONHUMAN; PUTAMEN; RAT; RECEPTOR AFFINITY; ANIMAL; AUTORADIOGRAPHY; BRAIN; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; AUTORADIOGRAPHY; BINDING, COMPETITIVE; BRAIN; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 0032502365     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(98)00148-9     Document Type: Article

References (16)

1. 1 P. SOKOLOFF, B. GIROS, M.-P . MARTRES, M.L. BOUTHENET, and J.-C. SCHWARTZ, Nature 347 146-151 (1990).
2. 2. B. LEVANT, Pharmacol. Rev. 49 231-252 (1997).
3. 3 K.D. BURRIS, M.A PACHECO, T.M. FILTZ, M.P. KUNG, H.F. KUNG, and P.B. MOLINOFF, Neuropsychopharmacology 12 335-345 (1995).
4. 4. B. LEVANT, D.E. GRIGORIADIS, and E.B. DE SOUZA, Eur. J. Pharmacol. 278 243-247 (1995).
5. 5. L. TANG, R.D. TODD, A. HELLER, and K.L. O'MALLEY, J. Pharmacol. Exp. Ther. 268 495-502 (1994).
6. 6. B. LEVANT, and E.B. DE SOUZA, Synapse 14 90-95 (1993).
7. 7. B. LEVANT, D.E. GRIGORIADIS, and E.B. DE SOUZA, J. Pharmacol. Exp. Ther. 264 991-1001 (1993).
8. 8. B. LEVANT, D.E. GRIGORIADIS, and E.B. DE SOUZA, J. Pharmacol. Exp. Ther. 262 929-935 (1992).
9. 9. T. KENAKIN, Pharmacol. Rev. 48 413-463 (1996).
10. 10. R.G. MACKENZIE, D. VANLEEUWEN, T.A. PUGSLEY, Y.H. SHIH, S. DEMATTOS, L. TANG, R.D. TODD, and K.L. O'MALLEY, Eur. J. Pharmacol. 266 79-85 (1994).
11. 11. S.B. FREEDMAN, S. PATEL, R. MARWOOD, F. EMMS, G.R. SEABROOK, M.R. KNOWLES, and G. MCALLISTER, J. Pharmacol. Exp. Ther. 286 417-426 (1994).
12. 12. G.N. BANCROFT, K.A. MORGAN, R.J. FLIETSTRA, and B. LEVANT, Neuropsychopharmacology (in press).
13. 13. P. SOKOLOFF, M. ANDRIEUX, R. BESANÇON, C. PILON, M.-P. MARTRES, B. GIROS, and J.-C. SCHWARTZ, Eur. J. Pharmacol. 225 331-337 (1992).
14. 14. T.A. PUGSLEY, M.D. DAVIS, H.C. AKUNNE, R.G. MACKENZIE, Y.H. SHIH, G. DAMSMA, H. WIKSTROM, S.Z. WHETZEL., L.M. GEORGIC, L.W. COOKE, S.B. DEMATTOS, A.E. CORBIN, S.A. GLASE, L.D. WISE, D. DIJKSTRA, and T.G. HEFFNER, J. Pharmacol. Exp. Ther. 275 1355-1366. (1995).
15. 15. M.J. MILLAN, J.L. PEGLION, J. VIAN, J.M. RIVET, M. BROCCO, A. GOBERT, A. NEWMAN TANCREDI, C. DACQUET, K. BERVOETS, S. GIRARDON, V. JAQUES, C. CHAPUT, and V. AUDINOT, J. Pharmacol. Exp. Ther. 275 885-98 (1995).
16. 16. S. CHUMPRADIT, M.P. KUNG, J. VESSOTSKIE, C. FOULON, M. MU, and H.F. KUNG, J. Med. Chem. 37 4245-4250 (1994).